case_images: PMC6489092_01
case_images: Trends of Hb and Ferritin in time with respect to cycles and IL-10 dosing. Relationship between levels of Hb, and Ferritin over time in relation to RBC infusion and IL-10 dosing.
case_images: cro-0012-0297-g01.jpg
case_images: PMC6489092_01_cro-0012-0297-g01.jpg
case_images: F1
case_images: Hb levels at the end of cycle 2 (6/13/2018) revealed no change in Hb (Fig. 1). However, by the end of the 3rd cycle of therapy (6/30/2018), the patient experienced a grade III anemia with a hemoglobin drop to 6.6 g/dL with no evidence of bleeding or hemolysis.
case_images: PET-CT scan images for Patient #01 prior (A) and 4 months following (B) treatment with Nivolumab + AM0010.
case_images: cro-0012-0297-g02.jpg
case_images: PMC6489092_01_cro-0012-0297-g02.jpg
case_images: F2
case_images: Four months following treatment initiation (9/4/2018), PET-CT scan revealed marked reduction in SUV from 11.2 to below pathogenic level, 2.7 in the RUL and no evidence in tumor activity in the adrenal glands (Fig. 2).